Intelligence / Healthtech / De Novo Grants / Firalis SA
Approvalsnovel device granted (FDA De Novo)12 Jun 2025
Firalis SA
12 Jun 2025: Novel device granted (FDA De Novo) · APO-Easy Genotyping kit. Recorded in the openFDA device 510(k) (De Novo decisions).
- Granted
- 12 Jun 2025
- Device
- APO-Easy Genotyping kit
- Specialty
- Immunology
- Product Code
- SFC
- Country
- France
- Location
- Huningue, France
- Submitted
- 2024-06-21
- Reference
- DEN240032
What this signal means
A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.
- 2 added in the 30 days to 19 Nov 2026.
- Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS
Find the decision makers at Firalis SA
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.
More in Immunology
De Novo Grants
Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.